AR054514A1 - Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1 - Google Patents

Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1

Info

Publication number
AR054514A1
AR054514A1 ARP060102721A ARP060102721A AR054514A1 AR 054514 A1 AR054514 A1 AR 054514A1 AR P060102721 A ARP060102721 A AR P060102721A AR P060102721 A ARP060102721 A AR P060102721A AR 054514 A1 AR054514 A1 AR 054514A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
substituted
heterocyclyl
halogen
Prior art date
Application number
ARP060102721A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR054514A1 publication Critical patent/AR054514A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Las composiciones que contienen dichos compuestos y a su utilizacion para el tratamiento y prevencion de la insuficiencia cardíaca cronica, la hipertension, isquemia de miocardio y de las infecciones por el virus de la hepatitis C (HCV) y para la prevencion de la adicion a los opioides. Reivindicacion 1: Un compuesto de formula (1), en la que: R1 es H o alquilo C1-6, en el que el grupo alquilo C1-6 está sustituido o sustituido por uno o más grupos OH, halogeno o NH2; y R2 es fenilo, cicloalquilo C3-10 o un grupo heterociclilo C4-10 que están insustituidos o sustituidos por 1, 2 o 3 restos independientemente seleccionados de: alquilo C1-6; alquenilo C2-6; alquinilo C2-6; alquilenoC1-6-COOH; alquilenoC1-6-C(O)O- alquiloC1-6; alquilenoC1-6-C(O)NH2; alquilenoC1-6-C(O)NH-alquiloC1-6; alquilenoC1-6 -O-alquiloC1-6; alquilenoC1-6-OH; alquilenoC1-6-NH2; alquilenoC1-6-NH-alquiloC1-6; alquilenoC1-6-N[alquiloC1-6]2; CN; COOH; alquiloC1-6C(O)O; C(O)NH2; alquiloC1-6C(O)NH; C(O)N(alquiloC1-6) 2; alquiloC1-6C(O); halogeno; -NH2; alquiloC1-6NH; N(alquiloC1-6)2; alquiloC1-6NH-C(O); OH; alquiloC1-6O; alqueniloC2-6O; alquiniloC2-6O; aquilenoC1-6O-C(O)OH; alquilenoC1-6-C(O)O-alquiloC1-6; alquilenoC1-6O-C(O)NH2; alquilenoC1-6O- C(O)NH-alquiloC1-6; alquilenoC1-6-OH; alquilenoC1-6O-O-alquiloC1-6; alquilenjoC1-6O-NH2; alquilenoC1-6O-NH-alquiloC1-6; alquiloC1-6O-C(O); alquiloC1-6-S; alquiloC1-4S(O)2; ariloaC6-10; heterociclilo C4-10; alquilenoC1-6-ariloC6-10; alquilenoC1-6- heteterocicliloC4-10; alquilenoC1-6-O-ariloC6-10; alquilenoC1-6-O- heterocicliloC4-10; arilo C6-10; heterocicliloC4-10O; alquilenoC1-6O-ariloC6-10; alquilenoC1-6-O-heterocicliloC4-10; en la que los grupos arilo C6-10 y heterociclilo C4-10 en los restos 40 a 49 están insustituidos o sustituidos por 1, 2 o 3 restos independientemente seleccionados de OH, halogeno, NH2, O-alquiloC1-6, alquilo C1-6, S(O)2-alquiloC1-4 o cicloalquilo C3-10; y/o están sustituidos en las proximidades por un resto de formula -O-(CH2)n-O-, en la que n es 1, 2 o 3 y en la que uno o más átomos de hidrogeno pueden estar sustituidos por átomos de halogeno; y R3 es H; alquilo C1-6 o O-alquiloC1-6, en la que el grupo alquilo C1-6 está insustituido o sustituido por OH, halogeno, NH2, alquiloC1-6NH o N(alquiloC1-6)2; o cicloalquilo C3-10, en la que el cicloalquilo C3-10 está sustituido o sustituido por uno o más átomos de fluor; o una de sus sales fisiologicamente aceptables.
ARP060102721A 2005-06-27 2006-06-23 Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1 AR054514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05013774 2005-06-27

Publications (1)

Publication Number Publication Date
AR054514A1 true AR054514A1 (es) 2007-06-27

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102721A AR054514A1 (es) 2005-06-27 2006-06-23 Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1

Country Status (30)

Country Link
US (1) US7910602B2 (es)
EP (1) EP1899333B1 (es)
JP (1) JP5010594B2 (es)
KR (1) KR20080020638A (es)
CN (1) CN101208340B (es)
AR (1) AR054514A1 (es)
AT (1) ATE423118T1 (es)
AU (1) AU2006264044A1 (es)
BR (1) BRPI0612320A2 (es)
CA (1) CA2611296A1 (es)
CY (1) CY1110464T1 (es)
DE (1) DE602006005242D1 (es)
DK (1) DK1899333T3 (es)
ES (1) ES2322197T3 (es)
HR (1) HRP20090244T2 (es)
IL (1) IL188381A0 (es)
MA (1) MA29498B1 (es)
MX (1) MX2007015829A (es)
MY (1) MY139016A (es)
NO (1) NO20080392L (es)
NZ (1) NZ564757A (es)
PL (1) PL1899333T3 (es)
PT (1) PT1899333E (es)
RS (1) RS50821B (es)
RU (1) RU2415855C2 (es)
SI (1) SI1899333T1 (es)
TW (1) TW200800982A (es)
UY (1) UY29632A1 (es)
WO (1) WO2007000241A1 (es)
ZA (1) ZA200709853B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
US20210403468A1 (en) * 2018-10-24 2021-12-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314355A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
BR0313262A (pt) * 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
EP1611131B1 (en) * 2003-02-27 2010-09-15 Palau Pharma, S.A. Pyrazolopyridine derivates

Also Published As

Publication number Publication date
HRP20090244T1 (en) 2009-06-30
RU2415855C2 (ru) 2011-04-10
NO20080392L (no) 2008-02-28
MA29498B1 (fr) 2008-05-02
KR20080020638A (ko) 2008-03-05
JP5010594B2 (ja) 2012-08-29
SI1899333T1 (sl) 2009-08-31
RU2008102970A (ru) 2009-08-10
HRP20090244T2 (en) 2009-07-31
ZA200709853B (en) 2008-12-31
EP1899333A1 (en) 2008-03-19
UY29632A1 (es) 2007-01-31
CA2611296A1 (en) 2007-01-04
CN101208340A (zh) 2008-06-25
TW200800982A (en) 2008-01-01
WO2007000241A1 (en) 2007-01-04
BRPI0612320A2 (pt) 2010-11-09
JP2008543957A (ja) 2008-12-04
MY139016A (en) 2009-08-28
MX2007015829A (es) 2008-02-22
DE602006005242D1 (de) 2009-04-02
PT1899333E (pt) 2009-04-23
RS50821B (sr) 2010-08-31
PL1899333T3 (pl) 2009-07-31
AU2006264044A1 (en) 2007-01-04
CN101208340B (zh) 2010-12-22
EP1899333B1 (en) 2009-02-18
CY1110464T1 (el) 2015-04-29
NZ564757A (en) 2009-12-24
US7910602B2 (en) 2011-03-22
DK1899333T3 (da) 2009-06-15
ATE423118T1 (de) 2009-03-15
ES2322197T3 (es) 2009-06-17
IL188381A0 (en) 2008-04-13
US20080227777A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
AR054514A1 (es) Derivados de pirazolopiridina como inhibidores del receptor beta-adrenergico cinasa 1
PE20070141A1 (es) Derivados de isoquinolina como inhibidores de rho-cinasa
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
RU2008145701A (ru) Производные пурина для применения в качестве агонистов аденозинового рецептора a2a
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
PE20110679A1 (es) Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20071035A1 (es) DERIVADOS DE ESTER O ACIDO ACETICO COMO MODULADORES DEL RECEPTOR CRTh2
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
PE20091732A1 (es) Dihidropirazolonas sustituidas y su uso
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
DK1689742T3 (da) Quinoloncarboxylsyreforbindelser med 5-HT-receptor-agonistisk aktivitet
PE20081657A1 (es) Derivados de ftalazina como antagonistas de los receptores de histamina h1
PE20220252A1 (es) Compuestos de pirrol
AR052302A1 (es) Derivados de sulfonamidas, procesos de preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal